657 studies found for:    Epoetin alfa OR Epogen, Procrit[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Withdrawn Epoetin Alfa for HIV-Associated Neuropathy Trial
Conditions: HIV Infections;   Neuropathy
Intervention: Drug: epoetin alfa
2 Completed An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)
Conditions: Anemia;   HIV Infections
Intervention: Drug: Epoetin alfa
3 Completed An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)
Condition: HIV Infections
Interventions: Drug: Filgrastim;   Drug: Epoetin alfa;   Drug: Zidovudine
4 Terminated A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients
Conditions: Anemia;   HIV
Intervention: Drug: epoetin alfa
5 Completed A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy
Conditions: Acquired Immunodeficiency Syndrome;   Anemia
Intervention: Drug: epoetin alfa
6 Completed A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease
Conditions: Anemia;   Acquired Immunodeficiency Syndrome
Intervention: Drug: epoetin alfa
7 Completed A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy
Conditions: Acquired Immunodeficiency Syndrome;   Anemia
Intervention: Drug: epoetin alfa
8 Completed A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease
Conditions: Anemia;   Acquired Immunodeficiency Syndrome
Intervention: Drug: epoetin alfa
9 Completed A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex
Conditions: HIV Infections;   Cytopenias
Interventions: Drug: Filgrastim;   Drug: Epoetin alfa;   Drug: Zidovudine
10 Completed A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
Conditions: HIV Infections;   Cytopenias
Intervention: Drug: Epoetin alfa
11 Completed The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic
Conditions: HIV Infections;   Cytopenias
Intervention: Drug: Epoetin alfa
12 Completed The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT
Conditions: HIV Infections;   Cytopenias
Intervention: Drug: Epoetin alfa
13 Completed A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia
Conditions: HIV Infections;   Cytopenias
Intervention: Drug: Epoetin alfa
14 Completed A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
Conditions: HIV Infections;   Cytopenias
Intervention: Drug: Epoetin alfa
15 Completed A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
Conditions: HIV Infections;   Cytopenias
Intervention: Drug: Epoetin alfa
16 Completed Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV
Condition: HIV Infections
Interventions: Drug: Peginterferon alfa-2a, Ribavirin, epoetin-β;   Drug: Peginterferon alfa-2a + Ribavirin for 12 weeks
17 Completed Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens
Conditions: Hepatitis C;   HIV Infections
Interventions: Drug: Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week;   Drug: Ribavirin (Copegus®) 1600 mg/day;   Drug: Epoetin β (450 UI/kg/week)
18 Completed Treatment Program for Anemia in AIDS Patients
Conditions: HIV Infections;   Cytopenias
Intervention: Drug: Epoetin alfa
19 Active, not recruiting Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Conditions: Anemia;   Chronic Kidney Disease (CKD)
Interventions: Drug: HX575 epoetin alfa;   Drug: US-licensed epoetin alfa
20 Active, not recruiting HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
Condition: Chronic Kidney Disease
Intervention: Drug: HX575 epoetin alfa (Sandoz)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years